+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypertrophic Cardiomyopathy Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896254
  • Report
  • June 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Bayer AG
  • Gilead Sciences, Inc
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease caused by a mutation in sarcomere protein genes which encodes for the contractile machinery of the heart which is characterized by an increase in left ventricular wall thickness which causes left ventricular outflow obstruction, diastolic dysfunction, myocardial ischemia, and mitral regurgitation. Symptoms of the hypertrophic cardiomyopathy are fatigue, dyspnea, chest pain, palpitations, and syncope.

According to the World Health Organization (WHO), an estimated 17.9 million people died from cardiovascular diseases in the year 2016, which accounts 31% of all global deaths. Increase in obese and sedentary lifestyle population, increasing cases of cardiac diseases are the major driving factors in the hypertrophic cardiomyopathy therapeutics market.

Key Market Trends

Calcium Channel Blockers Segment is Expected to Hold a Major Market Share in Hypertrophic Cardiomyopathy Therapeutics Market

Calcium channel blockers or calcium channel antagonists or calcium antagonists are most commonly used as antihypertensive drugs which act by reducing the amount of calcium that goes into the cardiac muscle cells and cause them to relax. Calcium channel blockers are used to alter the heart rate, reduce chest pain, and to prevent cerebral vasospasm more effective compared to beta-blockers in the treatment of cardiovascular disorders. Furthermore, rising geriatric population and obesity are also the major factors driving the market.

North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America expected to hold significant market share in the global hypertrophic cardiomyopathy (HCM) market due to the rising prevalence of congestive heart failure, sedentary lifestyles of individuals in the united states.

As per The Centers for Disease Control and Prevention (CDC), more than five million people are suffering from heart failure diseases in the United States, and about half of the affected population die within five years of diagnosis. Moreover, the existence of a developed healthcare care system and affordable reimbursement policies for the treatment of cardiovascular diseases is anticipated to positively reinforce the growth.

Competitive Landscape

The Hypertrophic Cardiomyopathy Therapeutics Market is moderately consolidated competitive and consists of of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently domianting the market are Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astra Zeneca Plc
  • Bayer AG
  • Gilead Sciences, Inc
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Obese and Sedentary Lifestyle Population
4.2.2 New Product Development for Targeted Cardiac Disorders
4.3 Market Restraints
4.3.1 Technological Advancement in Devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Antiarrhythmic Agents
5.1.2 Anticoagulants
5.1.3 Beta Adrenergic Blocking Agents
5.1.4 Calcium Channel Blockers
5.1.5 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astra Zeneca Plc
6.1.2 ADVANZ PHARMA Corp (Concordia Healthcare Corp)
6.1.3 Bayer AG
6.1.4 Gilead Sciences, Inc
6.1.5 Merck & Co., Inc
6.1.6 Mylan N.V.
6.1.7 Novartis AG
6.1.8 Pfizer, Inc
6.1.9 Sanofi S.A.
6.1.10 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • Astra Zeneca Plc
  • ADVANZ PHARMA Corp (Concordia Healthcare Corp)
  • Bayer AG
  • Gilead Sciences, Inc
  • Merck & Co., Inc
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll